206 related articles for article (PubMed ID: 12042653)
1. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
Koch M; Niemeyer G; Patel I; Light S; Nashan B
Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
Praditpornsilpa K; Avihingsanon Y; Kupatawintu P; Songpanich S; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; O-Charoen R; Tungsanga K
Transplant Proc; 2004 Mar; 36(2 Suppl):487S-491S. PubMed ID: 15041394
[TBL] [Abstract][Full Text] [Related]
4. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
Bumgardner GL; Ramos E; Lin A; Vincenti F;
Transplantation; 2001 Aug; 72(4):642-7. PubMed ID: 11544424
[TBL] [Abstract][Full Text] [Related]
5. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
6. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
Vincenti F; Nashan B; Light S
Transplant Proc; 1998 Aug; 30(5):2155-8. PubMed ID: 9723424
[No Abstract] [Full Text] [Related]
7. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
8. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
Nashan B; Light S; Hardie IR; Lin A; Johnson JR
Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
[TBL] [Abstract][Full Text] [Related]
9. Effect of immunosuppressive regimen on acute rejection and liver graft function.
Ziolkowski J; Paczek L; Niewczas M; Senatorski G; Oldakowska-Jedynak U; Wyzgal J; Foroncewicz B; Mucha K; Zegarska J; Nyckowski P; Zieniewicz K; Patkowski W; Krawczyk M; Ziarkiewicz-Wroblewska B; Gornicka B
Transplant Proc; 2003 Sep; 35(6):2281-3. PubMed ID: 14529915
[TBL] [Abstract][Full Text] [Related]
10. Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study.
Li J; Li X; Tan M; Lin B; Hou S; Qian W; Li B; Zhang D; Zhou B; Wang H; Zhu T; Guo Y
MAbs; 2009; 1(1):49-55. PubMed ID: 20046574
[TBL] [Abstract][Full Text] [Related]
11. Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.
Tkaczuk J; Yu CL; Baksh S; Milford EL; Carpenter CB; Burakoff SJ; McKay DB
Am J Transplant; 2002 Jan; 2(1):31-40. PubMed ID: 12095053
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab induction in solid organ transplantation.
Wiland AM; Philosophe B
Expert Opin Biol Ther; 2004 May; 4(5):729-40. PubMed ID: 15155164
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab.
Mottershead M; Neuberger J
Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
Wiseman LR; Faulds D
Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
[TBL] [Abstract][Full Text] [Related]
15. A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study.
Washburn WK; Teperman LW; Heffron TG; Douglas DD; Gay S; Katz E; Klintmalm GB
Liver Transpl; 2006 Apr; 12(4):585-91. PubMed ID: 16456831
[TBL] [Abstract][Full Text] [Related]
16. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
[TBL] [Abstract][Full Text] [Related]
17. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
[TBL] [Abstract][Full Text] [Related]
18. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
[TBL] [Abstract][Full Text] [Related]
19. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.
ter Meulen CG; Jacobs CW; Wetzels JF; Klasen IS; Hilbrands LB; Hoitsma AJ
Transplantation; 2004 Jan; 77(2):281-6. PubMed ID: 14742994
[TBL] [Abstract][Full Text] [Related]
20. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
Joyal D; Cantarovich M; Cecere R; Giannetti N
Clin Transplant; 2004 Oct; 18(5):493-6. PubMed ID: 15344949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]